Promising Results For VX-770, An Oral Investigational Agent That Targets A Defective Protein Responsible For Cystic Fibrosis

At the 31st European Cystic Fibrosis Society (ECFS) Annual Meeting in Prague, Czech Republic, researchers presented interim results from the first clinical trial of the investigational oral agent VX-770 in cystic fibrosis patients.

More: continued here

Filed under: Cystic Fibrosis on June 19th, 2008